Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Jefferies Financial Group

Analysts at Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued on Monday, Benzinga reports. The brokerage set a “buy” rating and a $165.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price objective suggests a potential upside of 29.84% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Citigroup lowered their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Royal Bank of Canada increased their price target on Sarepta Therapeutics from $181.00 to $182.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Finally, Raymond James reiterated an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Trading Up 2.3 %

Shares of SRPT stock opened at $127.08 on Monday. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a market cap of $12.01 billion, a price-to-earnings ratio of 1,155.27 and a beta of 0.82. The stock has a 50-day moving average of $129.00 and a 200-day moving average of $132.36.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.27) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post 1.45 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Blue Trust Inc. grew its stake in shares of Sarepta Therapeutics by 896.5% during the 3rd quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 511 shares during the period. VitalStone Financial LLC purchased a new stake in Sarepta Therapeutics during the third quarter valued at about $327,000. UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Sarepta Therapeutics during the third quarter worth about $1,624,000. Finally, Handelsbanken Fonder AB increased its stake in shares of Sarepta Therapeutics by 12.3% in the third quarter. Handelsbanken Fonder AB now owns 23,815 shares of the biotechnology company’s stock worth $2,974,000 after purchasing an additional 2,600 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.